---
id: senolytics-therapy
name: Senolytics Therapy
family: technological
tier: emerging
url: https://futuremap.talin.digital/e/senolytics-therapy/
license: CC-BY-NC-4.0
---

# Senolytics Therapy

## In short
Drugs that selectively kill senescent cells — cells that have stopped dividing but persist, secreting inflammatory signals, accumulating with age.

The biology is one of the better-supported mechanisms in ageing research. Clearing senescent cells in mice extends healthy lifespan and improves function across several tissues, and that result has replicated. The candidate compounds are largely repurposed drugs, which shortens the path.

Technical readiness 4 against societal readiness 6, and that two-point gap is the entry's point. The appetite for a treatment that slows ageing is close to unlimited, human trials are early and have produced mixed results, and the space between those two facts is already full of supplements sold on the strength of the mouse data. Chapter 14's mechanism is operating here in a consumer market rather than a policy one.

**Common misconception:** that the mouse results transfer. Interventions that extend mouse lifespan have a long history of not extending human lifespan, and this one is at the beginning of finding out.

## Readiness
TRL 4 · SRL 6 · gap -2 · **hype risk**

Source: WKO Innovation Map 26/27 (2026)

## Candidate megatrends (UNREVIEWED)
- Longevity and the Healthspan Gap (longevity-and-the-healthspan-gap)
- The Care Economy (the-care-economy)
- The Silver Economy (the-silver-economy)
- Precision Everything (precision-everything)

These are derived from this technology's cluster, not from a judgement about this technology. They are a starting point for review, not a claim.
